非小细胞肺癌第一代 EGFR - TKI 耐药后的治疗进展

摘要

肺癌是世界上最常见的恶性肿瘤，严重威胁着人们的生命健康。表皮生长因子受体酪氨酸激酶抑制剂（EGFR - TKI）已成为非小细胞肺癌的研究热点。表皮生长因子受体酪氨酸激酶抑制剂为表皮生长因子受体基因突变患者的首选治疗方案，可用于非小细胞肺癌的一线治疗、二线治疗以及维持治疗。但随着疾病的进展，肿瘤不可避免产生耐药，从而导致治疗失败。本文就非小细胞肺癌第一代表皮生长因子受体酪氨酸激酶抑制剂耐药后的治疗作一综述。%Lung cancer is one of the most common malignant tumors in the world and a serious threat to human health. EGFR - TKI has become the hot topic in non - small cell lung cancer. EGFR - TKI is the first - line treatmen on EGFR gene mutations in lung cancer,EGFR - TKI has been used for first - line therapy,second - line treatment and main-tenance therapy in non - small cell lung cancer. Although the results of EGFR - TKI for patients with non - small cell lung cancer has been effective,with the progression of the disease,it inevitably may lead to durg resistance. In this paper,we made a review on the treatment after resistance to first generation EGFR - TKI in patients with non - small cell lung cancer.